Panbela Therapeutics Inc expected to post a loss of 25  cents a share - Earnings Preview

Panbela Therapeutics

12/08/2022 21:39

* Panbela Therapeutics Inc  PBLA.OQ   PBLA.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 15. 
    * ​Refinitiv's mean analyst estimate for Panbela
Therapeutics Inc
is for a loss of 25 cents per share. For the same quarter last
year, the company reported a loss of 22 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Panbela
Therapeutics Inc is $6​, above​ its last closing price of $1.37.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.25       -0.25      -0.27     Missed  -5.9
 Dec. 31 2022  -0.19       -0.18      -0.26     Missed  -44.4
 Sep. 30 2021              -0.23      -0.16     Beat    30.4​
 Jun. 30 2021  -0.22       -0.18      -0.22     Missed  -24.5
 ​​Mar.        -0.11       -0.11      -0.23     Missed  -109.1
 31 2021                                                
 Dec. 31 2020  -0.18       -0.16      -0.09     Beat    45.5​
 Sep. 30 2020  -0.12       -0.12      -0.21     Missed  -75
 This summary was machine generated August 12 at 20:39 GMT.  All
figures in US dollars  unless otherwise stated